Lonza's SSP for Early Phase Delivery

Authors

  • Beat Schmidt

DOI:

https://doi.org/10.2533/000942905777676885

Keywords:

Cgmp, Cmo, Investment, Lonza, Small-scale plant

Abstract

Lonza, the leading custom manufacturer of chemical intermediates and active ingredients as well as biopharmaceuticals for the pharmaceutical and agrochemical industries, has recently expanded into a new state-ofthe-art seven-storey small-scale plant (SSP) whose task is to satisfy both clinical supply and process development with sophisticated and lean cGMP-compliant equipment. With this investment, Lonza has now closed the gap between kilo lab and launch plant in order to provide one-stop shopping for API and drug product developmentthrough-approval.

Downloads

Published

2005-01-01